Leukemia can be cured in some people, but not all types respond the same way

Whether leukemia is curable depends on which type you have, your age, and how your body responds to treatment. Some people achieve remission—a state where cancer cells are no longer detectable—and stay cancer-free for decades or life. Others reach remission but face the possibility of relapse. A smaller group does not respond to standard treatment at all. The word "cured" means different things in oncology than it does for infections: doctors typically consider someone cured of leukemia if they remain in remission for five years or more without treatment, though some people relapse after that point.

The most curable types are acute lymphoblastic leukemia (ALL) in children and some forms of chronic leukemia caught early. Acute myeloid leukemia (AML) in adults has lower cure rates but still produces remission in a meaningful portion of patients. Chronic myeloid leukemia (CML) has changed dramatically since targeted drugs became available—many people now live for decades with the disease controlled by medication rather than cured in the traditional sense.

Key Takeaways

  • Remission—the absence of detectable cancer cells—is the first goal of leukemia treatment, and some people remain in remission for life.
  • Cure rates vary sharply by leukemia type: childhood ALL has the highest cure rate at roughly 85 to 90 percent, while adult AML is lower at around 30 to 40 percent depending on age and genetics.
  • Younger patients generally have better outcomes than older ones, and genetic features of the cancer itself predict response to treatment.
  • Even after remission, some people experience relapse, which is why long-term follow-up care and monitoring remain important.

How remission differs from cure

Remission means that tests—usually bone marrow biopsy and blood work—show no detectable leukemia cells. It does not necessarily mean the cancer is gone forever. Complete remission is the standard goal: fewer than 5 percent of blast cells (immature cancer cells) in the bone marrow, and normal blood counts. Achieving complete remission is the foundation for any chance at long-term survival.

Doctors call someone "cured" when they have been in continuous remission for five years or longer without treatment. This threshold exists because most relapses happen within the first few years after treatment ends. However, some people do relapse after five years, and a small number relapse even after ten or twenty years. The longer someone stays in remission, the lower the statistical risk of relapse becomes, but the risk never reaches zero for all types.

This is why your oncologist will talk about "survival rates" and "remission rates" rather than simply saying "cured." The distinction matters: a person in remission is living with leukemia controlled, not necessarily eliminated.

Cure rates by leukemia type

Acute lymphoblastic leukemia in children has the highest cure rate of any leukemia. Roughly 85 to 90 percent of children with ALL achieve long-term remission with modern chemotherapy and sometimes stem cell transplant. This dramatic improvement happened over the past 30 years as treatment protocols became more refined. Adults with ALL have lower cure rates—around 40 to 50 percent—because their disease tends to be more aggressive.

Acute myeloid leukemia in adults has cure rates that depend heavily on age and the genetic makeup of the cancer cells. Younger adults (under 60) achieve complete remission in 60 to 70 percent of cases, and roughly 30 to 40 percent remain in long-term remission. Adults over 60 have lower rates, partly because their bodies tolerate intensive chemotherapy less well. Certain genetic mutations in the leukemia cells—like FLT3 or TP53 mutations—predict worse outcomes, while others like NPM1 mutations predict better ones.

Chronic myeloid leukemia has transformed since tyrosine kinase inhibitors (drugs like imatinib, dasatinib, and nilotinib) became standard treatment in the early 2000s. These targeted drugs control the disease so effectively that many people live normal lifespans without ever entering traditional remission. The disease is managed as a chronic condition rather than cured, but survival has improved dramatically.

Chronic lymphocytic leukemia (CLL) in adults is rarely cured with standard chemotherapy alone, though newer targeted drugs and immunotherapies are changing outcomes. Some people live for many years with stable disease; others progress more quickly.

Factors that predict whether treatment will work

Age is one of the strongest predictors. Children tolerate intensive treatment better and their leukemia cells often respond more readily to chemotherapy. Adults over 65 have worse outcomes across all acute leukemia types, both because their bodies handle treatment toxicity less well and because their leukemia cells tend to have more unfavorable genetic features.

The genetic profile of the leukemia cells themselves matters enormously. Doctors now routinely test for mutations and chromosomal abnormalities—like t(15;17) in acute promyelocytic leukemia, which has an excellent prognosis, or complex karyotype in AML, which predicts poor response. These tests help oncologists choose which drugs to use and give realistic estimates of remission likelihood.

How quickly the leukemia responds to the first round of treatment is another strong indicator. If someone achieves complete remission after the initial chemotherapy, their long-term outlook is better than if remission takes multiple rounds or does not happen at all. The disease burden at diagnosis—how many blast cells are present—also matters: higher counts at the start generally predict worse outcomes.

What happens after remission is achieved

Once remission is confirmed, treatment typically continues for months to years depending on the leukemia type. For acute leukemias, this usually means additional chemotherapy cycles to reduce the risk of relapse. For some patients, particularly those at high risk of relapse or those with certain genetic features, stem cell transplant may be recommended. This procedure replaces the patient's bone marrow with healthy stem cells from a donor (or sometimes the patient's own cells collected before relapse).

After active treatment ends, monitoring becomes the focus. Patients return for blood work and bone marrow biopsies at gradually lengthening intervals—weekly or monthly at first, then every few months, then annually. These visits check for any sign of leukemia returning. Some people remain in remission indefinitely; others see leukemia cells reappear months or years later. A second remission is sometimes possible with different drugs or a transplant, but outcomes for relapsed leukemia are generally worse than for initial treatment.

Newer treatments and emerging options

CAR-T cell therapy, approved for certain acute leukemias and lymphomas, has produced remissions in patients who failed standard chemotherapy. This treatment involves removing immune cells from the patient, engineering them to recognize leukemia cells, and infusing them back. Response rates are high, though not everyone responds and some experience severe side effects.

Venetoclax combined with hypomethylating agents has improved outcomes for older adults with AML who cannot tolerate intensive chemotherapy. Targeted drugs for specific mutations—like FLT3 inhibitors or IDH inhibitors—are being added to standard regimens to improve remission rates.

These advances mean that cure rates and remission rates are gradually improving, particularly for patients diagnosed in recent years. However, progress varies by leukemia type, and access to newer drugs depends on geography, insurance, and clinical trial availability.

Living with leukemia after remission

People in remission from leukemia often face long-term side effects from chemotherapy or stem cell transplant, including heart problems, secondary cancers, infertility, and cognitive changes. These effects can appear years after treatment ends. Regular follow-up with an oncologist helps catch these complications early.

The psychological weight of leukemia does not end with remission. Many people experience anxiety about relapse, particularly around the time of follow-up appointments. Support groups, counseling, and connections with others who have had leukemia can help with this adjustment.

Frequently Asked Questions

Can children with leukemia be cured?

Yes, most children with acute lymphoblastic leukemia can be cured with modern chemotherapy. Roughly 85 to 90 percent achieve long-term remission. Children with acute myeloid leukemia have lower cure rates, around 60 to 70 percent, depending on genetic features of their disease.

What does it mean if leukemia comes back after remission?

Relapse means leukemia cells have reappeared in the blood or bone marrow. A second remission is sometimes possible with different chemotherapy, targeted drugs, or stem cell transplant, but outcomes are generally worse than for initial treatment. The time between remission and relapse matters—relapse within a year typically predicts a poorer prognosis than relapse after several years.

Is chronic leukemia curable?

Chronic myeloid leukemia is usually managed as a chronic disease with targeted drugs rather than cured. Many people live normal lifespans on these medications. Chronic lymphocytic leukemia is rarely cured with standard treatment, though newer drugs are improving outcomes and some people live for many years with stable disease.

How long do people typically live after leukemia remission?

This varies widely by leukemia type, age, and individual factors. Children with ALL who achieve remission often live normal lifespans. Adults with AML in remission have median survivals ranging from a few years to over a decade depending on age and genetics. People with CML on targeted drugs often live for decades.

Can leukemia relapse years after remission?

Yes, though it is less common. Most relapses happen within the first two to three years after treatment ends. Relapses after five or more years in remission do occur but are rare. This is why doctors consider five years of continuous remission a marker of cure, though some risk of late relapse remains.